Boiron SA (BOIRF)
OTCMKTS · Delayed Price · Currency is USD
24.00
0.00 (0.00%)
At close: Aug 6, 2025
Paramount Global Revenue
In the year 2024, Boiron had annual revenue of 487.56M EUR, down -1.15%. Boiron had revenue of 259.21M in the half year ending December 31, 2024, a decrease of -6.58%.
Revenue
487.56M EUR
Revenue Growth
-1.15%
P/S Ratio
0.86
Revenue / Employee
175.95K EUR
Employees
2,771
Market Cap
434.86M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 487.56M | -5.69M | -1.15% |
| Dec 31, 2023 | 493.25M | -40.99M | -7.67% |
| Dec 31, 2022 | 534.24M | 79.04M | 17.36% |
| Dec 31, 2021 | 455.20M | -58.38M | -11.37% |
| Dec 31, 2020 | 513.58M | -43.54M | -7.82% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Elite Pharmaceuticals | 84.04M |
| Glass House Brands | 215.62M |
| American Oncology Network | 1.76B |
| Northwest Biotherapeutics | 1.47M |
| Silence Therapeutics | 27.17M |
| Global Cord Blood | 196.10M |